Cigna sued Bristol Myers Squibb on Tuesday, accusing the drugmaker of violating U.S. antitrust law by keeping generic versions of its blockbuster blood cancer drug Pomalyst off the market so it could ...

Pomalyst, which treats multiple myeloma and Kaposi sarcoma in adults, can cause side effects. Learn about its more common, mild, and serious side effects.

Bristol Myers BMY depends on newer drugs like Opdualag, Reblozyl and Breyanzi to stabilize its revenue base as its legacy drugs face generic competition. Legacy Portfolio is adversely impacted due to ...

Bristol Myers Squibb has been accused in a new lawsuit of using fraudulent patents and other illegal tactics to maintain its monopoly on blockbuster blood cancer drug Pomalyst for years after it ...

Celgene announced that the FDA has approved Pomalyst (pomalidomide) for the treatment of patients with relapsed and/or refractory multiple myeloma.

Insurance company Cigna claims Bristol Myers Squibb may have caused overpayments of ‘billions’ of dollars after allegedly ...

Cigna (NYSE:CI) on Tuesday filed an antitrust lawsuit accusing Bristol Myers Squibb (NYSE:BMY) of breaching U.S. competition rules by maintaining a monopoly over its blockbuster blood cancer drug ...

Cigna claims Bristol Myers’ Celgene unit filed sham lawsuits it knew it was unlikely to win in an effort to protect its ...

Pomalyst plus Velcade with dexamethasone improves survival outcomes for patients with relapsed/refractory multiple myeloma, according to a phase 3 trial.

Bristol Myers and Celgene are being sued in an antitrust suit, alleging they used fraud, sham litigation, and reverse payments to delay cheaper generics of Pomalyst.

A lawsuit which accused Bristol Myers Squibb of anticompetitive tactics in protecting the market exclusivity of Pomalyst has been dismissed.

In 2022, Pomalyst generated nearly $3.5 billion (₹30,000 crore) in revenue, marking a 5% increase from the previous year. See Also: Viacom18 Scores Big Again Bagging Exclusive ISL Broadcasting ...